In order to compare between in vivo toxicity studies, dosimetry is needed to translate study-specific dose regimens into dose metrics such as tissue concentration. These tissue concentrations may then be compared with in vitro bioactivity assays to perhaps identify mechanisms relevant to the lowest observed effect level (LOEL) dose group and the onset of the observed in vivo toxicity. Here, we examine the perfluorinated compounds (PFCs) perfluorooctanoate (PFOA) and perfluorooctanesulfonate (PFOS). We analyzed 9 in vivo toxicity studies for PFOA and 13 in vivo toxicity studies for PFOS. Both PFCs caused multiple effects in various test species, strains, and genders. We used a Bayesian pharmacokinetic (PK) modeling framework to incorporate data from 6 PFOA PK studies and 2 PFOS PK studies (conducted in 3 species) to predict dose metrics for the in vivo LOELs and no observed effect levels (NOELs). We estimated PK parameters for 11 combinations of chemical, species, strain, and gender. Despite divergent study designs and species-specific PK, for a given effect, we found that the predicted dose metrics corresponding to the LOELs (and NOELs where available) occur at similar concentrations. In vitro assay results for PFOA and PFOS from EPA's ToxCast project were then examined. We found that most in vitro bioactivity occurs at concentrations lower than the predicted concentrations for the in vivo LOELs and higher than the predicted concentrations for the in vivo NOELs (where available), for a variety of nonimmunological effects. These results indicate that given sufficient PK data, the in vivo LOELs dose regimens, but not necessarily the effects, could have been predicted from in vitro studies for these 2 PFCs.
In vivo toxicity studies are often characterized by the no observed effect level (NOEL) and/or the lowest observed effect level (LOEL) dose groups for a given toxic outcome (Martin et al., 2009) . Even if the pharmacodynamic mechanism is conserved, comparing LOELs between studies is confounded by differences in pharmacokinetics (PK), which can be not only biological in origin (eg, species and gender) but also due to dose regimen (eg, spacing, magnitude, duration, and route of administration). If, however, the test compound activates a consistent mode of action across studies, then somewhere between the NOEL and the LOEL, the tissue concentrations must be sufficient to perturb that mechanism in a statistically significant number of test animals (Allen et al., 1994) . If that mode of action is conserved in humans, then the chemical exposures that might cause these effects in humans may be inferred (Boobis, 2010) .
The ToxCast study of the U.S. Environmental Protection Agency (U.S. EPA) comprises hundreds of high-throughput, chiefly in vitro assays investigating a large number of chemicals, including perfluorinated compounds (PFCs) Reif et al., 2010) . Known chemical toxicants have been examined in ToxCast in order to develop in vitro signatures of chemical toxicity for application to chemicals with little or no in vivo toxicological data Martin et al., 2011; Sipes et al., 2011) . These signatures of toxicity are developed by correlating observed in vitro activitypositive assay results-with actual in vivo toxicity (Blaauboer, 2010) .
In order to interpret in vitro assay bioactivity, the biochemical perturbation characterized by that assay and the in vivo context of that perturbation must be identified . If the in vitro concentrations that cause activity are consistent with the transition region from NOEL to LOEL in vivo, then an empirical association may exist between that in vitro activity and the observed in vivo toxicity. We hypothesize that those assays that are consistent with the transition from NOEL to LOEL in many in vivo studies may help to identify the underlying mechanism of toxicity.
Here, we use 2 PFCs-perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA)-as model chemicals for comparing in vivo toxicity and in vitro bioactivity. PFCs are long-chain fatty acid analogs with fluorine atoms in the place of all hydrogen atoms. Among the ToxCast chemicals, PFOS and PFOA are of particular interest because measurable levels are detected in the general population of the United States Olsen et al., 2012) and elsewhere in the world (Harada et al., 2010; Haug et al., 2009) . PFOS and PFOA are relatively well studied chemicals; toxicity studies with PFOS and PFOA in adult rodents and monkeys have documented LOELs for liver effects and maternal LOELs for developmental endpoints in offspring (Lau et al., 2004 .
The PK of PFOA is known to be nonlinear (Andersen et al., 2006; Lou et al., 2009) , and the half-life for elimination from the body can vary between species and genders by many orders of magnitude . In occupationally exposed workers, the elimination half-life has been estimated to be from 2.3 to 3.8 years (Bartell et al., 2010; Olsen et al., 2007) . The long human half-lives are in contrast to hours for female rats, days for male rats, and weeks for mice, and about a month for monkeys . The PK behavior of PFOS is less studied but has been modeled as being generally similar to that of PFOA (Andersen et al., 2006; Chang et al., 2012) . This study has 2 major goals: First, we wish to examine the concordance of various measures of internal exposure for the available toxicological in vivo studies. This metaanalysis of 9 PFOA and 13 PFOS studies is performed using PK data drawn from 6 PFOA and 2 PFOS PK in vivo studies. The PK data are analyzed within a Bayesian framework that allows prediction across species, strains, and genders, in order to identify consistent measures of exposure, ie, dosimetric anchors.
Second, we evaluate the correlation between these in vivo effects and observed in vitro activities. Recently Aylward and Hays (2011) have noted general concordance between the in vitro activation concentrations and the serum concentrations at the end of toxicity studies. For metabolizing enzymes, Bjornsson et al. (2003) described a heuristic for extrapolation of in vitro bioactivities to possible or likely in vivo activity; here, we extend this comparison between a range of in vitro bioactivities (the ToxCast assay suite) with in vivo serum concentration time courses.
MATErIALS AND METHODS

Data Sources
In vivo toxicity data sets. Toxicity data including study design, LOELs and, where available, NOELs from 9 PFOA studies and 13 PFOS studies are summarized in Tables 1 and 2 , respectively. Toxicity endpoints were categorized as liver, thyroid, developmental, reproductive, or immunological. Where available, serum values at study termination are also reported.
PK data sets. For each species/strain/gender combination that was considered, a single distribution of parameters was determined that should be most consistent with all the available data.
PFOA PK was modeled for 3 species: cynomolgus monkeys (Butenhoff et al., 2004b) , Sprague Dawley rats , and 2 strains of mice. The data from the 2 strains of mice were separately analyzed: CD1 (Lou et al., 2009 ) and C57Bl/6 (Dewitt et al., 2008) . Due to the pronounced difference in the PK of male and female rats for PFOA, the 2 genders were fit separately. Because a significant gender difference has not been observed in mice and more female data were available (Lou et al., 2009) , only the female data were used. For monkeys, the majority of data were for males; however, a small amount of data were used from experiments on both male and female monkeys that were administered compound iv. The female data were analyzed with the assumption that the only difference between the genders for monkey was body weight (BW) (the half-life in monkeys is believed to be only slightly different between genders). The PFOA PK data are summarized in Table 3. PFOS PK was modeled for 3 species: cynomolgus monkeys (Chang et al., 2012; Seacat et al., 2002) , Sprague Dawley rats (Chang et al., 2012) , and CD1 mice (Chang et al., 2012) . The PFOS PK data are summarized in Table 4 .
ToxCast in vitro data. The pilot (phase I) of the ToxCast program measured the activity of 309 compounds (U.S. E.P.A., 2010), including PFOA and PFOS, against a suite of in vitro assays provided by separate vendors using different technologies including cell-based and biochemical (cell-free) assays. Most chemical assay combinations were run in concentration-response format and from each concentration-response curve, it was determined statistically whether the chemical was active or not. If found active, a characteristic concentration (AC 50 -the concentration at which 50% of maximum activity was seen) and maximum efficacy (E max ) were determined. The data are described in Judson et al. (2010) . All data and additional assay information are available from the ToxCast web site (http:/www.epa.gov/ncct/toxcast) and from the Aggregated Computational Toxicology Repository (http://www.epa.gov/actor/).
Results from 3 ToxCast technology platforms in which PFOS and PFOA were active are reported here. The first, contracted from Attagene, Inc (Research Triangle Park, NC; www.attagene.com), consisted of 2 highly multiplexed assays; one with 48 human transcription factor DNA-binding sites controlling reporter gene expression (denoted CIS) and the other with 25 human nuclear receptor (NR) superfamily members using a mammalian 2-hybrid, GAL4 system (TRANS) , both in the HepG2 human hepatoma cell line. The second platform, contracted from BioSeek, Inc (South San Francisco, CA) (www.bioseek.com), used the biologically multiplexed activity profiling (BioMAP) platform for assaying cellular signaling pathways in complex, cocultured, primary human cell systems (Houck et al., 2009) . The third, contracted from NovaScreen (Hanover, MD) (www.caliperls.com), was an array of 292 biochemical assays including receptor binding and enzyme inhibition .
The efficacy (E max ) and potency (inverse of AC 50 ) for all active assays are shown in Figure 1 . Efficacy was scaled by a fold change or percent activity cutoff that depended upon the variability of the specific assay technology; a doseresponse curve with a scaled efficacy of 1 would be at the cutoff and therefore filtered for not showing a significant change over background. For PFOA, there were 12 active ToxCast assays, whereas PFOS was more promiscuous, with 52 assays indicating activity. The 3 assays common to both PFOS and PFOA are described in Table 5 In Figure 1 , 5 PFOS assays are only marginally above the assay cutoff: BSK_BE3C_PAI1_down, BSK_3C_SRB_down, and BSK_BE3C_hLADR_ down for the BioSeek technology and NVS_ENZ_hAKT2 and NVS_ENZ_ hGSK3b for the NovaScreen technology (see Supplementary Table 2 for assay descriptions). For PFOA, the BioSeek BSK_SM3C_SAA_up assay is only marginally above the cutoff.
PK Model
The PK model for PFCs (depicted in Fig. 2 ) was adapted with minor modifications from Andersen et al. (2006) . The primary parameters are defined in the caption of Figure 2 . The salient feature of the Andersen et al. (2006) model is that the free concentration of PFCs in the central compartment (given by free*C 1 ) is cleared to a filtrate compartment where it is either excreted or resorbed via a saturable process with a Michaelis-Menten form. The Andersen et al. (2006) model was modified to include a gut compartment from which PFCs were absorbed using a first-order rate constant k a .
The flow through the filtrate (Q fil ) is determined by multiplying a fraction (Q filc ) times the cardiac output, which is scaled by BW to the power 0.74. Only the free chemical in the central compartment (free*C 1 ) flows to the filtrate. The volume of the central compartment (V c ) and the volume of the filtrate (V fil ) are determined by, respectively, multiplying BW by the fractions V cc and V filc , respectively. The flow between the central and secondary compartments (Q d ) is determined from multiplying V c by the rate of flow from the central compartment to the second (k 12 ). The maximum rate of the saturable resorption Michaelis-Menten kinetics (T maximum ) is scaled by multiplying a constant (T maxc ) by BW.
In the original Andersen et al. (2006) analysis, the deep tissue (secondary) compartment was characterized in terms of the rates to and from that compartment (k 12 and k 21 , respectively). This corresponds to a volume of distribution V 2 = k 12 × V 1 /k 21 , so that the ratio of the volume of the second compartment to the first, R v2:v1 = k 12 /k 21 . The original model was modified to enforce the assumption that the primary (serum) compartment contains a significant portion of the PFCs: the volume of distribution in the deep tissue compartment was constrained to be no more than 100 times greater than the volume of the serum-in effect this is an upper limit on the fraction of PFCs sequestered within tissue. For this reason, the ratio of the 2 volumes is estimated, rather than the rate from the second compartment to the first compartment. The rate of flow from the deep tissue back to the serum was calculated as k 21 = k 12 /R v2:v1 .
The model was implemented using R (version 2.10.0, R Development Core Team, 2012) and solved with the deSolve package (version 1.5, Soetaert et al., 2010) .
Bayesian Analysis
Statistical model. A nonhierarchical model for parameter values was assumed; ie, there is a single value shared by all individuals of the same species/strain (with rat further subdivided by gender). BW and treatment (number and magnitude of doses) are the only parameters that may vary between individuals; however, with the exception of the data, individual BWs were not available so that an average BW was determined for each combination of species and gender. Measurement errors were assumed to be log-normally distributed, with each combination of study and tissue type having a separate measurement SD that was estimated as part of the statistical analysis.
Sampler. Bayesian analysis was performed using Markov Chain Monte Carlo (MCMC) . The MCMC sampler, implemented as an R package, was developed and used by Garcia, Wambaugh, Kenyon, Ibrahim, and Setzer (in preparation). The Metropolis-Hastings algorithm (Hastings, 1970; Metropolis et al., 1953) was used to find the posterior distributions for each parameter such that the predictions of the PK model are consistent with the data and the prior assumptions. A multivariate proposal distribution for the PK parameters and measurement variances was determined from several initial runs starting with the Lou et al. (2009) Priors. Bayesian analysis allows formal inclusion of prior knowledge in the form of set distributions on the parameters being estimated ; however, that empirical PK parameters can have a wide range of plausible values (Wambaugh et al., 2008) . We chose vague, bounded prior distributions that are intended to be significantly informed by the data. For all estimated parameters, the prior knowledge was assumed to be distributed log normally. This constrained the parameters to positive values. The mean and variances assumed for the CD1 mice, male and female Sprague Dawley rats, and cynomolgus monkeys are given in Supplementary Table 1 . For the analysis of PFOA in C57Bl/6 mice, the available data were insufficient to achieve a converged statistical analysis, so the posterior parameter distributions for the CD1 mouse, with the variances increased 10-fold, were used as a prior. The priors for measurement variances were uniform between 0 and 5.
Convergence. The crux of a Bayesian analysis is assessing whether the distributions of values in the Markov Chain reflect the posterior distributions of the statistical model given the priors and the data. Each distribution of parameter values was considered to be "burned in" (ie, drawn from the true posterior and independent of the assumed starting values) when they passed the Heidelberger and Welch stationarity test (Heidelberger and Welch, 1983) as implemented in the Convergence Diagnosis and Output Analysis Software for Gibbs sampling output (CODA) Package (Best et al., 1995) for R.
Predicted Dose Metrics
Using these appropriately parameterized PK models for serum as a function of dose and time, a variety of predictions can be made. For each study with a toxicological endpoint and LOEL, the time-integrated serum concentration (area under the curve or AUC), average serum concentration, and maximum serum concentration were determined over the course of the in vivo study. All dose metrics were calculated using the total serum concentration of compound. Generally, it was assumed that animals were observed at the end of dosing. However, for the Butenhoff et al. (2009) PFOS study, 2 different AUCs were calculated-gestational only (for the male offspring endpoint) and gestational plus 20 days postnatal (for the maternal endpoint). This separation of the 2 exposures neglects lactational transfer of compound, which was not modeled. For many of the in vivo studies, a serum concentration at euthanasia was measured, and for these studies, a final serum concentration was predicted at the time corresponding to euthanasia.
For each estimated PK parameter, MCMC produces a series of values that, taken as a whole, represent the distribution of parameter values consistent with the data and the priors. These parameter distributions can in turn be used to generate distributions of predictions, eg, average serum concentration or AUC. If there is large parameter uncertainty for parameters that greatly influence the predicted value, then the distribution of predicted values will be wide. If the quantity being predicted is not sensitive to the uncertain parameter, then the distribution of the predicted value will be unaffected. Assessing parameter uncertainty allows appropriate confidence in model predictions.
Determination of Transition Concentrations
The distributions of PK predictions were used to demark the transition region from NOEL to LOEL, ie, the region of predicted dose metrics containing the lowest chemical dose that causes an observable toxic effect. The transition region for each in vivo study treatment is bounded by the upper 95% confidence value of the distribution of average serum concentrations calculated for the LOEL and, if available, the lower 95% confidence value for the NOEL. If no NOEL was available, an arbitrary lower value, LOEL/100, was used.
When multiple in vivo studies examined the same toxicity endpoints, the transition regions from the studies can be used jointly to further refine the transition region. Transition regions were calculated in 2 ways: the intersection of all studies for a given chemical and toxicity was more restrictive, using the highest NOEL and the lowest LOEL, whereas the union of all studies was broader in that the lowest NOEL and the highest LOEL was used. In some cases, the exposures calculated for the in vivo studies conflicted, producing a NOEL in one study in excess of the LOEL in the other study. In this case, no intersecting transition region was identified and only the union region was available.
Determination of Benchmark Dose
For 3 PFOA studies where there was no NOEL dose group but the effect per dose group data were available, a benchmark dose (BMD) was estimated using the U.S. EPA Benchmark Dose Software v2.3.1. 
rESuLTS
Nine PFOA in vivo studies and 13 PFOS in vivo studies were examined for monkeys, rats, and 2 strains of mice, in some cases, for separate genders. We predicted dose metrics, including the average serum concentration, for the LOEL dose group for each endpoint in each study and, where available, the NOEL dose group. For many of the PFOA studies, a NOEL group was lacking (ie, the lowest dose tested showed an effect), and for three of these NOEL study-endpoint combinations, there were sufficient data available to perform a BMD analysis.
Analysis of In Vivo PK Data Sets
In the absence of ideal PK data for either PFOS or PFOA, a range of possible PK model predictions that were equally consistent with the data were generated with Bayesian statistical analysis. Each dose metric predicted from this analysis has a distribution of values consistent with the data, which we describe by a mean or median value and 95% credible interval; broader distributions reflect greater uncertainty.
Model predictions were assessed by comparing the predicted final serum concentration for each treatment with any measured final serum concentration in the in vivo toxicity experiments. The predictions (Fig. 3) were generally similar to the measurements (within a factor of 2). There were no systematic differences in the performance of the predictions for different species, genders, and strains despite the different PK data sets used. In Figure 3 , the credible intervals are smaller than the scatter of the points around the perfect predictor (1:1) linebecause these predictions do not perfectly match the measured serum concentrations, there remains uncertainty about the PK behavior that has not been fully characterized. The specific predicted values are reported in Supplementary Tables 3-6 .
Because the uncertainty of the parameters depends on the amount of available data, it is unsurprising that the distributions of parameter values are larger for those test animals with less data (Tables 3 and 4) . Because most of the available PK studies were not designed to probe nonlinear phenomena (eg, saturable resorption), parameters describing the saturable resorption process are especially uncertain. These parameters have been difficult to estimate in previous studies (Andersen et al., 2006; Lou et al., 2009) . However, the form of the saturable resorption model seems to be an appropriate empirical description of the PK for PFCs (Lou et al., 2009) . Time course plots comparing the predictions for the median parameter values and the data used for estimating the parameters are available in Supplementary Figures 1-13. PFOA PK parameters. The estimated PK parameters (median and 95% interval) for PFOA are presented in Table 6 . The parameter distributions generally appear biologically plausible: the median fraction of blood flow to the filtrate (Q filc ) was physiologically consistent and plausible (ie, less than or equal to the fraction of blood flow to the kidney) in all cases, but the uncertainty, as characterized by 95% credible interval, was quite large in some cases. Parameters for PFOA in male and female rats were similar, including the affinity of the putative resorption transporters, except that the maximum Michaelis-Menten transport rate was nearly 200 times greater for the males. This potentially corresponds to differences in either the expression of the relevant transporters or their activity, which would be consistent with the postulated estrogen-mediated downregulation of PFOA transporters in rats (Kudo et al., 2002) . For the mouse and female rat, the median fraction of blood flow to the filtrate (Q filc ) was physiologically relevant (less than or equal to the fraction of blood flow to the kidney) and the 95% credible intervals were within the range of the cardiac output.
Central Compartment
(V c , C 1 , free) Andersen et al. (2006) pharmacokinetic model with oral absorption. A gut is the amount of chemical in the gut; k a is the first-order rate constant for absorption from the gut; Q fil is the flow through the filtrate compartment; C 1 , C 2 , and C 3 are the chemical concentrations in the central, second, and filtrate compartments, respectively; V c , V t , and V fil are the volumes of distribution of the central, second, and filtrate compartments; free is the free fraction of compound in the central compartment; Q d is the flow between the central and second compartments; the saturable resorption process from the filtrate back into the central compartment is modeled with Michaelis-Menten kinetics, with a maximum rate T maximum and a half-maximum concentration K T . The estimated flow to the filtrate was more uncertain for the male rat and cynomolgus monkey: the medians were larger than physiologically plausible (Davies and Morris, 1993) , 22% and 15%, respectively, but the 95% credible intervals spanned 3 orders of magnitude.
PFOS PK parameters. The estimated PK parameters (median and 95% interval) for PFOS are presented in Table 7 . Parameters for the male mouse were extremely uncertain, leading to relatively large credible intervals on predicted dose metrics. This uncertainty reflects a combination of the limited amount of data (only 2, single-dose treatments-see Table 4 ) and perhaps the inappropriateness of the model used. For other species and genders, the PFOS data were relatively more certain. The PK data for PFOS in male and female rats and monkeys were consistent with the saturable resorption interpretation of nonlinear PK. The median male and female rat parameters were dissimilar, but the difference was not statistically significant. The median fraction of blood flow to the filtrate (Q filc ) was physiologically relevant for the male and female rats but appeared too high for the mouse and monkeys. Curran et al. (2008) reported a final serum concentration of PFOS in male and female rats 4-8 times less than was predicted by the calibrated model. Because the PK model does well for other studies, this discrepancy appears to indicate either a problem with our characterization of that study (eg, assumptions about dose received from feed) or differences with the analytical chemistry method used.
Comparison of Dose Metrics
The full PK parameter distributions from the analysis of in vivo PK data were used to predict the 95% credible intervals for dose metrics corresponding to each LOEL and NOEL treatment group. Details for all predicted dose metrics corresponding to each LOEL are reported in Supplementary Tables 7 and 8 . Figure 4 illustrates the consistency of predicted internal dose metrics corresponding to the LOEL for each in vivo study, given each study's respective treatment regimen. For each dose metric, in vivo endpoint, and chemical combination, the dose metrics for the various studies are scaled by the average value of the dose metric across those studies and the deviation from that average is plotted.
PFOA dose metrics. The mean and maximum serum concentrations appear to be the most consistent dose metrics in Figure 4 , with most scaled values near zero (small deviation from perfect) despite the occasional outlier study. This is in agreement with Rodriguez et al. (2009) in which PFOA in vivo toxicological studies with similar toxicity endpoints in rats and mice differed by 30-fold (3 and 0.1 mg/kg/day, respectively) in administered dose. By investigating the PK for the 2 different LOELs, Rodriguez et al. (2009) Kemper (2003) Kemper (2003) Butenhoff et al. effects, the outliers with respect to total dose and AUC are from the 180-day monkey study . Although that study had a LOEL of 3 mg/kg/day, which is superficially similar to the LOELs of the other studies, the total dose of 540 mg/kg is a clear outlier with respect to the other studies. The AUC for the 180 day study is also an outlier relative to the more acute studies. For both PFOA hepatic and developmental effects, the most consistent dose metrics are mean and maximum serum concentration. 
PFOS dose metrics. For PFOS immunological effects
Analysis of the Onset of In Vivo Effects
For each observed in vivo effect in Figures 5 and 6 , the 95% credible interval of the predicted mean serum concentration dose metrics can be used to identify a transition region between the NOEL and LOEL groups. In this way, we identify whether or not there is a mean serum concentration that corresponds to the onset of each effect that is consistent across studies (and therefore between species). If there is no NOEL dose group, all we know is that the effect happened somewhere between the mean concentration for no dose (zero) and the dose metric for the LOEL dose group. However, we can assume that at an arbitrary level of LOEL/100, there may be no activity detected. In Tables 8 and 9 , the transition regions of mean serum concentrations from NOEL to LOEL are organized by endpoint, using information across all species and studies to bracket a transition region in which PFOS or PFOA may have initiated toxic events.
Onset of PFOA effects. Figure 5 compares the predicted mean serum concentration dose metric corresponding to the LOEL treatment group for each PFOA in vivo study. Where available, the dose metric for the NOEL treatment groups is also shown, but for most PFOA studies, the lowest dose group had an effect (ie, the lowest dose group is the LOEL and there is no NOEL). Regardless of species or endpoint, the LOELs in Figure 5 appear to be roughly consistent. Although the lack of NOELs for most studies makes it hard to evaluate whether this is simply a consequence of dose spacing, the number of studies and varying kinetics between species and genders makes it unlikely that this consistency is entirely due to chance. In Table 8 , the transitions from NOEL to LOEL for PFOA are organized by endpoint. Perfluorooctane sulfonic acid
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Liver (10) Developmental (6) Immunotoxicity (1) Mean Conc. Max Conc. AUC Total Dose   FIg. 4 . Consistency of predicted dose metrics across various in vivo toxicity studies for perfluorooctanesulfonate (left) and perfluorooctanoate (right). All metrics have been normalized by taking the difference from the mean value and dividing by the mean. Original units for administered dose were either mg/kg BW or mg/kg BW/day. All 3 dose metrics (mean and maximum serum concentration and AUC) for each in vivo study are presented in Supplementary  Table 7 . These estimated internal doses are slightly higher than Rodriguez et al. (2009) , which found that a dose of 1 mg/kg/day in the Lau et al. (2006) study results in an AUC of 9864 mg/l·h (converted from an average daily AUC of 548 mg/l·h by multiplying by 18 days) compared with the estimate of 19 600 (686) mg/l·h reported here.
Onset of PFOS effects. In Figure 6 , the PFOS in vivo effects have been compared using the predicted mean serum concentration dose metric across studies, species, and genders. Unlike for PFOA, the presence of NOELs for most PFOS studies allows clear argument that the dose metrics are generally consistent. The LOELs and NOELs for the 3 studies with thyroid effects are entirely consistent, but for each of liver-specific, developmental, reproductive, and immunological effects, there is 1 outlier study (eg, a study with a NOEL predicted higher than LOELs of the other studies). In Table 9 , the window of concentrations for the transition from NOEL to LOEL for PFOS is organized by endpoint, and due to the outlier studies, only thyroid effects have an intersection transition region (ie, a transition region that is consistent for all studies).
The LOELs and NOELs for liver effects are consistent for 4 studies, but the Curran et al. (2008) female rat LOEL is lower than the NOEL for the other 4 studies, including the Curran et al. (2008) male rat study. For developmental effects, the LOELs and NOELs are consistent for 4 studies, but the Lau et al. (2003) mouse study has a NOEL higher than the LOELs of the other studies (which were all rat studies). For the 3 studies showing reproductive effects, the Chen et al. (2012) LOEL is higher than the NOEL for the Luebker et al. (2005a) study.
Immunological effects for PFOS appear to be much more sensitive than the other endpoints observed. However, there is disagreement between the predicted dose metrics for the Dong et al. (2009) All 3 dose metrics (mean and maximum serum concentration and AUC) for each PFOS in vivo study are presented in Supplementary Table 8.
FIg. 5. Average serum concentration during perfluorooctanoate (PFOA)
in vivo toxicity studies and in vitro activities. Box and whisker plots indicate median, mean ± SD, and 95% credible intervals for lowest observed effect level (LOEL) and no observed effect level (NOEL) (lower of 2 points when NOEL was observed). Credible intervals are calculated using the distribution of pharmacokinetic model parameters for the animal and dose regimen used in each in vivo study. The shaded region between LOEL and NOEL indicates toxicity transition region. Horizontal bars indicate the ToxCast PFOA in vitro AC 50 s (concentrations) from Figure 1 for cell-based (solid line) and binding (dashed line) assays. The horizontal bars are plotted translucently, so that denser lines indicate multiple active assays. Black boxes indicate benchmark doses, which could be calculated for 3 studies only. The in vitro assay AC 50 s are numbered in order of potency starting at 1 (most potent), as in Table 10 .
FIg. 6.
Average serum concentration during perfluorooctanesulfonate (PFOS) in vivo toxicity studies and in vitro activities. Box and whisker plots indicate median, mean ± SD, and 95% credible intervals for lowest observed effect level (LOEL) and no observed effect level (NOEL) (lower of 2 points when NOEL was observed). Credible intervals are calculated using the distribution of pharmacokinetic (PK) model parameters for the animal and dose regimen used in each in vivo study. The shaded region between LOEL and NOEL indicates toxicity transition region. Horizontal bars indicate the ToxCast PFOS in vitro AC 50 s (concentrations) from Figure 1 for cell-based (solid line) and binding (dashed line) assays. The horizontal bars are plotted translucently, so that denser lines indicate multiple active assays. The in vitro assay AC 50 s are numbered in order of potency starting at 1 (most potent), as in Table 11 .
Comparison With In Vitro Data
The 95% credible interval of the dose metrics for the LOEL and NOEL (or LOEL/100) demarked a transition region within which biological perturbations sufficient to produce a phenotypic toxic response may be presumed to occur (Tables 8 and  9 ). If the AC 50 for an in vitro assay lies within a NOEL-LOEL transition region, then the bioactivity characterized by that assay occurs at a concentration higher than that of the lowest NOEL dose group and lower than those of the highest LOEL group.
The coincidence of specific assays with specific effects is summarized in Tables 10 and11, where a "weak" coincidence is an overlap between one or more NOEL-LOEL transition regions for a specific endpoint, and a "strong" coincidence is an overlap with the NOEL-LOEL transition regions for all studies for a specific endpoint.
Tables 10 and11 contain a column indicating whether or not an assay was active for both PFOS and PFOA. There are 3 such assays, which are described in Table 5 . Of them, only the NVS_ENZ_hTie2 assay can be easily correlated with a toxic effect, as Tie2 is associated with angiogenesis, a key process in development, and therefore potentially a mechanism for PFCinduced developmental toxicity . Both PFCs activate the NVS_ENZ_hBACE assay, and BACE is associated with Alzheimer's disease (Vassar et al., 2009 ), but this is not an endpoint that can be explored with the type of animal studies analyzed here. The activation of PXRE indicated by the ATG_PXRE_CIS assay for both chemicals is most likely an indicator of xenobiotic sensing only because PFCs are not metabolized.
Also summarized in Tables 10 and 11 is whether or not the given assay is an element of a published in vitro signature for toxicity. In Martin et al. (2011) , several in vitro assays were identified as being correlated with reproductive toxicity in rats (ie, an in vitro "signature" for rat reproductive toxicity). In Sipes et al. (2011) , separate in vitro signatures were developed for rat and rabbit developmental toxicity. Finally, in Kleinstreuer et al. (2011) and , an in vitro signature for vascular disrupters has been developed.
PFOA in vitro data. Twelve in vitro activities are listed for PFOA in Table 10 , and the corresponding concentrations are also plotted as horizontal lines in Figure 5 . The lack of NOELs for many of the PFOA studies produces broad transition regions: all assays that are below the LOELs for developmental endpoints appear consistent with those effects (ie, they activate at concentrations greater than the highest LOEL/100). Three assays are consistent with all NOELs and LOELs for the nonimmunological in vivo PFOA assays: NVS_ENZ_hTie2, ATG_PPARa_TRANS_perc, and ATG_ PPRE_CIS_perc. Where BMDs could be calculated, they coincide with the onset of in vitro activity.
As shown in Table 10 , 5 of the 12 PFOA-activated assays are part of the Martin et al. (2011) signature for rat reproductive toxicity. Only one of the active in vitro assays for PFOA is in the Sipes et al. (2011) rat developmental toxicity signature and none are in the signature for rabbit developmental toxicity. Four PFOA in vitro activities are consistent with the Kleinstreuer et al. (2011) vascular disruption signature. The cell-free ENZ_hTie2 assay from NovaScreen, which was also active for PFOS, activated in the transition region for all observed effects and was also present in the vascular disrupter toxicity signature.
PFOS in vitro data. The AC 50 s for the PFOS in vitro assays plotted in Figure 6 also seem to be generally consistent with the onset of potentially toxic endpoints. There were 52 assays in which activity was observed, of which only those assays active in one of the toxicity signatures or also found for PFOA are listed in Table 11 . The full list of active assays for PFOS is available in Supplementary Table 9 . In studies without a NOEL, LOEL/100 was assumed.
b Calculated exposures for 1 outlier study produced conflicting NOELs and LOELs so that no intersecting (common to all studies) transition region was identified. "S" indicates strong coincidence of in vitro activity with the toxicity transition region of the in vivo studies (intersect), whereas "W" indicates weak coincidence (union). "+" indicates that that assay is part of an in vitro signature of toxicity. Assays are numbered in the same order listed on the right-hand side of Figure 6 . Only those assays active in one of the toxicity signatures or also found for PFOA are shown-the full list of active assays is available in Supplementary Table 9. 322 Due to the different NOEL-LOEL transition regions for immunological effects and all other effects, the assays were divided into 2 different sets coincident with the transition regions. The 18 most potent assays are coincident with the immunological effects transition from LOEL to NOEL, and some of these assays are also found in the rat reproductive toxicity signature from Martin et al. (2011) .
Many other PFOS-activated in vitro assays (n = 40) are strongly coincident with the thyroid effects. Due to outlier in vivo toxicity studies, assays are only weakly consistent with the remaining effects. Six active assays are associated with the Martin et al. (2011) rat reproductive toxicity signature. Four active assays are associated with the 
DISCuSSION
This study provides dosimetry for 22 different toxicological in vivo studies across species, strains, and genders and compares predicted serum concentrations with in vitro concentrations necessary for activity in high-throughput assays. For a given effect, we found that the predicted dose metrics corresponding to the onset of that effect were generally consistent across gender and species, despite well-known differences in the PK. This consistency between studies suggests that rather than a singular "most sensitive" test animal and effect, there were multiple potential adverse effects occurring across species for a variety of dose regimens that produced mean serum concentrations of approximately 50µM for both PFOA and PFOS.
We also found that the concentrations that cause in vitro bioactivity from some ToxCast assays appear to be consistent with the predicted serum concentrations for the transition from NOEL to LOEL dose regimens. For both PFOS and PFOA, it appears that the onset of in vivo effects occurs for dose regimens that produce average concentrations in excess of concentrations needed to cause bioactivity in vitro. For the PFOS studies, which had several observed groups with no observed effect, the NOEL dose regimens produced concentrations too low to cause much bioactivity in vitro. Most of the PFOS in vitro activity occurs in a cluster between 11.6 and 30.1µM-a relatively narrow band of concentrations that are consistent with transition from NOEL to LOEL for all of the thyroid in vivo toxicity studies and most of the liver, developmental, and reproductive studies.
For PFOA, there are 2 clusters of activity among the PFOA in vitro data at approximately 5 and 50µM. Despite 9 PFOA in vivo studies, there were few NOEL dose groups, so it is hard to say which cluster predicts the onset of effects, although approximately 50µM is consistent with the BMD from the Wolf et al. (2007) study. For all but the Dewitt et al. (2008) liver effects, both clusters provide a conservative estimate of the needed serum concentration for observed effect, and the second cluster is within the 95% credible interval for the Dewitt et al. (2008) study. For both PFOA and PFOS, a conservative estimate of the dose regimens needed to produce nonspecific (ie, hepatic, thyroid, developmental, or reproductive) toxicity in vivo could have been predicted from in vitro bioactivity given sufficient PK data.
In order to facilitate dosimetric anchoring, we used a Bayesian framework to incorporate uneven amounts of PK data from 8 in vivo studies that used varying animals and dosing regimens. Model parameter distributions for a consistent PK model were estimated such that a 95% credible interval for each dose metric could be predicted. The breadth of the credible interval of the predicted dose metrics reflects the uncertainty corresponding to the appropriateness of the PK model used and the available in vivo PK data sets for each species, strain/stock, and gender.
The mean and maximum serum concentrations were both identified as being generally consistent dosimetric anchors. Choosing between them depends on understanding the mechanism of action: perhaps maximum serum concentration for acute effects as opposed to mean serum concentration for chronic effects.
PFOA is known to have dose-dependent (nonlinear) PK properties: though repeated doses rapidly accumulate to a quasi-equilibrium blood concentration, a single dose results in a much longer half-life than would be consistent with the rapid approach to quasi-equilibrium (Andersen et al., 2006; Lou et al., 2009) . Given its long half-life, using a linear PK model (eg, the 1-compartment model) to predict exposures resulting from multiple PFOA exposures results in large overestimates of reality (Butenhoff et al., 2004b; Lou et al., 2009) . The empirical saturable renal resorption model (Andersen et al., 2006) addresses this problem by allowing PFOA to reach steady state faster than the elimination half-life would indicate. Because it is an empirical model, species-specific parameters must be estimated using species-specific PK data.
A physiologically based PK model for PFCs might be preferable because it would allow extrapolation between species, provide better estimates of chemical-specific parameters, and allow estimation of chemical concentration in the specific tissues for which toxicity is observed. However, data for chemical-specific partitioning into most tissues exists only for PFOA, and then only from the single-dose rat study. We have found here that due to the dose selection of the study, the nonlinear PK of PFOA was not present. This is indicated by the very uncertain estimates of the Michaelis-Menten parameters for that study (Table 6) . If the nonlinear PK for PFCs is due to tissue partitioning (eg, binding or transport), then these processes would be missed by the data set. The serum, urine, and feces data from were found to be well fit by a linear, 2-compartment model using a single distribution of parameters for all doses in Wambaugh et al. (2008) . A more physiologically motivated PK model for PFOA in humans exists (Loccisano et al., 2011) , but, as with the Andersen et al. (2006) model, the elimination parameters cannot be extrapolated and must be empirically determined. Given the limitations of the available data for estimating parameters, the simpler Andersen et al. (2006) empirical PK model was preferable.
The general concordance observed in Tables 6 and 7 of the saturable resorption parameter estimates with kidney blood flow/ glomerular filtration rates provides support for the renal resorption interpretation of the Andersen et al. (2006) model. However, until a PK study with matched tissue and urine samples is conducted at doses resulting in nonlinear PK, the saturable resorption mechanism remains one plausible hypothesis among many (eg, sequestration in the liver, saturation of plasma protein binding), particularly because organic anion transporters are expressed in many tissues beyond the kidney proximal tubule.
Across the 9 in vivo studies for PFOA, the most sensitive toxic endpoint with respect to maximum and mean predicted serum concentration (all dose metrics given in Supplementary Tables 7 and 8) was for female C57BL/6N mice exposed to 0.94 mg/kg daily for 15 days via drinking water (average daily water consumption was used). In this study, increased absolute and relative liver weight was observed (Dewitt et al., 2008) . The 9 PFOA in vivo toxicity studies often lacked NOEL dose groups, indicating a need for lower doses in any future PFOA study designs.
Across the 13 in vivo studies for PFOS, immunological effects appear to occur at lower doses than other effects. The 3 lowest exposures corresponding to endpoints were all for CD1 mice, indicating that CD1 mouse is the most sensitive animal among those tested. The available PFOS PK data were minimal for these animals, so the dosimetry is more uncertain. However, the range of possible internal doses indicated by the Bayesian analysis does not overlap with other studies.
When we move beyond the in vivo toxicity studies to compare with the in vitro assays, we again observe some consistency. For PFOA, the cell-free human TIE2 (ENZ_hTie2) assay from NovaScreen activated in the transition region for all observed effects and was also active for nonimmunological PFOS effects. TIE2 is associated with angiogenesis, a key process in development, and therefore potentially a mechanism for PFC-induced developmental toxicity . For PFOS, the in vitro assays coincident with in vivo immunological effects included inhibition of multiple metabolizing enzyme (CYP 450) activities. This indicates that there is plausible PFOS biological activity at these relatively low concentrations (the most potent activity was 0.066µM). However, we are unaware of a linkage between the inhibition of CYP 450 and immunological endpoints. In 3 cases of missing NOEL groups for PFOA, sufficient data were available to estimate BMDs. Although a BMD does not allow analysis of which in vitro assays activated between the NOEL and LOEL groups, in two of the cases, the BMD was consistent with the onset of in vitro activity.
The diversity of molecular targets affected by either PFOS or PFOA across ToxCast is broad and includes many not previously associated with PFCs. The ToxCast in vitro assays are primarily screening assays; the concentrations tested are broadly spaced (typically 8 concentrations at half-log spacing from 100 to 0.01µM) and the off-the-shelf assays do not necessarily investigate the most relevant key events for PFCs. Therefore, these assays are not conclusive with respect to linking chemical effect to molecular target, eg, more definitive follow-up work would be required. However, because the range of AC 50 s across the targets lie in relatively narrow bands, an analysis based on these promiscuous activities may still be useful in defining the concentrations at which these chemicals interact with biological targets. Similar concordance between the serum levels demarking the transition from no effect to toxicity endpoint have been observed by Aylward and Hays (2011) for 5 ToxCast chemicals, including PFOA.
It remains to be seen whether, given sufficient PK knowledge, in vitro assays for other chemicals will correspond to in vivo effects. The lack of metabolism of PFCs makes comparison between in vitro bioactivity and the onset of endpoints in the in vivo toxicity studies more direct; however, there are still confounders of in vitro-in vivo extrapolation to be considered. Foremost is the fact that PFOA and PFOS bind well to serum albumin, leaving relatively little free compound to perturb biological activity (other than displacing other albumin substrates). Due to differences in the concentration of serum albumin present in the in vitro assays (the cell-free assays had none) and the concentration of serum albumin present in vivo, the concentrations necessary to produce the same free fraction of PFCs may have varied by as much as 2 orders of magnitude (Gulden and Seibert, 2003) .
Further, the frank concentration applied to the well may not reflect the concentration at the site of action. For both cell-free and cell-based in vitro assays, (1) the partitioning of compound between the wall of the well and proteins and lipids within the media and (2) the concentration within the cells themselves for cell-based assays are generally unknown (Zaldívar Comenges et al., 2012) . Though approaches exist for estimating well partitioning and media binding for many classes of organic compounds, these properties need to be investigated for PFCs.
Finally, most ToxCast assays are conducted in a concentration-response format and, if the response can be successfully fit with a Hill function, the concentration producing 50% maximal response activity (AC 50 ) was determined. In terms of toxicity, there is nothing necessarily unique about 50% activity; the AC 50 merely provides a reasonable representation of the potency of a chemical for a given target. A Hill fit with a typical biological slope of 1 has a range covering almost 2 orders of magnitude between the AC 10 and the AC 90 .
The observed coincidence between in vitro and in vivo concentrations indicates that these considerations may not be necessarily present or are offsetting in the case of PFOA and PFOS. However, the wide phase I ToxCast concentration ranges are not optimal for testing these hypotheses. Therefore, these results should be used to prioritize resources for targeted testing of PFOA and PFOS, eg, with a range of test concentrations that is denser than the half-log concentration spacing used for ToxCast screening.
Dosimetric anchoring via PK modeling demonstrated consistency between in vivo studies, 9 for PFOA and 13 for PFOS. Further, in vitro bioactivity data were consistent with in vivo dose response, suggesting that for these compounds, an estimate of the dose regimens needed to produce in vivo toxicity could have been predicted in vitro. Hogue (2012) indicates that there is a strong movement among international government bodies to phase out or ban long-chain PFCs in preference for shorter-chain PFCs worldwide. However, there is lack of toxicity information to address the potential adverse human health effects and environmental impacts of the shorter-chain PFCs. Therefore, it would useful to provide predicted toxicity dose regimens for the shorter-chain PFCs as they are considered for replacement of the long-chain PFCs. Given the current state of knowledge despite 22 in vivo toxicity studies, eg, many effects lacking NOELs, in vitro methods may provide a viable supplemental tool for hazard assessment.
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